Treatment of chronic granulomatous disease

Lentiviral vectors with a myeloid-specific miR223 promoter for CGD therapy address transactivation and silencing issues, ensuring long-term ROS restoration in phagocytic cells.

JP7586516B2Active Publication Date: 2024-11-19UNIVERSITY OF ZURICH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2022520041
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-10-02
Filing Date
2020-10-02
Publication Date
2024-11-19
Estimated Expiration
2040-10-02

AI Technical Summary

Technical Problem

Current gene therapy approaches for chronic granulomatous disease (CGD) face challenges such as transactivation leading to genomic instability, clonal dominance, and transgene silencing, which compromise long-term efficacy.

Method used

The use of lentiviral vectors transducing CD34+ hematopoietic stem cells with a functional variant of the NADPH oxidase enzyme complex under the control of a myeloid-specific miR223 promoter, avoiding enhancer elements to ensure tissue-specific and long-term expression.

Benefits of technology

This approach effectively restores ROS generation in phagocytic cells, overcoming transactivation and silencing issues, providing sustained therapeutic benefits for CGD patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007586516000008
    Figure 0007586516000008
  • Figure 0007586516000009
    Figure 0007586516000009
  • Figure 0007586516000010
    Figure 0007586516000010
Patent Text Reader

Abstract

The present invention relates to isolated human hematopoietic stem or progenitor cells transduced with a lentiviral vector comprising a coding nucleic acid sequence encoding a functional variant of a polypeptide selected from gp91phox, p22phox, p40phox, p47phox, p67phox and Rac2 under the transcriptional control of a promoter sequence comprising or consisting essentially of the miR223 promoter sequence (SEQ ID NO: 01). Based on this background, it is an object of the present invention to provide an efficient means for the treatment of genetic disorders in chronic granulomatous disease.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to means and methods for treating chronic granulomatous disease. [Background technology]

[0002] 2. Background of the Invention Chronic granulomatous diseases (CGD) constitute a group of congenital immunodeficiencies with an incidence between 1 / 19.230 in Saudi Arabia (Suliaman et al. (2009) Pediatric Asthma, Allergy & Immunology 22, 21-26) and 1 / 450.000 in Sweden (Ahlin et al. (1995) Acta Paediatr 84, 1386-1394). The diseases manifest themselves early in life, as the affected patient's body is unable to defend itself against bacterial and fungal infections. Life expectancy is strongly impaired, despite lifelong prophylactic treatment with antibiotics and antifungals (Kuhns et al. (2010) New Engl J Med 363 (27) 2600-10; van den Berg et al. (2009) PloS one 4(4): e5234). The primary cause of the disease is the greatly reduced or absent ability of phagocytes (granulocytes, monocytes, and macrophages) to generate reactive oxygen species (ROS) for pathogen inactivation due to defects in the phagocyte's NADPH (nicotinamide adenine dinucleotide phosphate) oxidase enzyme complex. The NADPH oxidase enzyme complex is composed of six subunits (gp91phox, p22phox, p40phox, p47phox, p67phox, and Rac2). In approximately 60% of all CGD patients, the disease is caused by mutations in the gp91phox subunit-encoding gene (CYBB) on the X chromosome, and is therefore referred to as X-CGD. Another approximately 30% of patients present with alterations in the autosomal recessive NCF1 gene (p47phox subunit) (p47phox-deficient form of CGD), while only 5% of cases are due to autosomal recessive mutations in p67phox and p22phox (Roos et al. (2003) Microbes Infect 5: 1307-15).

[0003] Gene therapy is a new treatment option for patients suffering from monogenic diseases. The principle of gene therapy in the current state of the art is to introduce a functional version of a mutated gene into the genome of diseased cells. Current clinical approaches rely heavily on the delivery of therapeutic genes by adeno-associated virus-based vectors or by retroviral (gammaretroviral or lentiviral) vectors. The inserted functional version of the mutated gene (transgene) results in the expression of a new gene product, which compensates for the absence of the native gene product. Since the first clinical success in 2000, the number of diseases for which clinical success has been achieved by this gene-adding approach of gene therapy has been continuously increasing.

[0004] The latest developments in designer nucleases (Zinc Finger Nucleases (ZFN), Transcription activator-like effector nucleases (TALEN), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR / Cas) methodology) allow sequence-specific gene modification (deletion or repair), and sequence-specific insertion of DNA. Sequence-specific gene disruption for therapeutic purposes has already found clinical application (TALEN: W. Quasim et al. (2015) Blood 126:2016; ZNF: ClinicalTrials.gov Identifier NCT02500849 and CRISPR / Cas9: Cyranoski D. et al. Nature 539,479; ClinicalTrials.gov Identifier: NCT03057912). Currently, only zinc finger nucleases are clinically evaluated for sequence-specific insertion to cure hemophilia B, MPS I and MPS II (https: / / www.sangamo.com / product-pipeline).

[0005] Currently, the only curative treatment for CGD is allogeneic hematopoietic stem cell (HSC) transplantation from a human leukocyte antigen (HLA)-matched donor. For up to approximately 75% of patients of unrelated European ancestry, an HLA-matched donor can be identified (Grager et al. (2014) N Engl J Med 371: 339-48). For the remaining 25%, gene therapy-based correction of autologous HSC represents an additional potentially curative treatment option.

[0006] Gene therapy for CGD is therefore a reasonable option for patients without an HLA-matched HSC donor. As learned from female carriers of X-linked CGD, NADPH oxidase activity above 20% can be associated with a healthy phenotype (Bjorgvinsdottir et al. (1997) Blood 89, 41-48; Kuhns et al. (2010) N Engl J Med 363, 2600-2610). Thus, a gene therapy correction level of approximately 20% NADPH oxidase activity is considered sufficient to achieve clinical success.

[0007] The first clinically successful phase I / II gene therapy trial in X-CGD patients was initiated in 2004 by University Children's Hospital Zurich and Johann Wolfgang Goethe University Hospital Frankfurt (NCT 00927134; NCT 00564759). Within this trial, two children were treated in Zurich and two adult patients were treated in Frankfurt. The gene therapy vector consisted of an LTR-driven (non-self-inactivating (SIN)) gamma retroviral vector carrying gp91phox-encoding cDNA as the transgene, which resulted in ubiquitous transgene expression. The study was clinically successful, as all four patients recovered from infections refractory to conventional treatment (Ott et al. (2006) Nat Med 12: 401-409; Siler et al. (2015) Curr Gene Ther 15: 416-427; Bianchi et al. (2009) Blood 114: 2619-2622). However, long-term follow-up revealed two serious adverse events (SAEs) that led to the closure of the trial in 2010: Transactivation: In clones in which the viral vector integrated adjacent to the MDS1-EVI1 gene, enhancer sequences present in the long terminal repeats of the gammaretroviral vector interacted with the promoter of the MDS1-EVI1 proto-oncogene (Evi1 transactivation) conferring a selective advantage to these HSC clones. This resulted in clonal dominance and genomic instability with monosomy 7 and the development of myelodysplastic syndromes (MDS) in three of four gene therapy treated patients. Silencing: The promoter of the viral vector is gradually methylated, which results in a decrease in expression of the therapeutic transgene (transgene silencing) and the re-emergence of CGD.

[0008] These SEAs are (I) Different integration profiles (e.g., use of different viral vectors) that prevent integration of the viral vector close to the MDS1-EVI1 gene; (II) tissue-specific transgene expression (i.e., only in myeloid-derived cells that require transgene expression, but not in HSCs) to prevent a potential selection advantage of HSC clones in the case of transactivation; and (III) preventing silencing of transgene expression over time to promote long-term efficacy; This mandated the development of safer gene therapy vectors based on lentiviral self-inactivating (SIN) vectors with

[0009] Terms and Definitions

[0010] The term "lentiviral vector" as used in the context of this specification refers to a virion or viral genome derived from a retrovirus and adapted for human gene therapy. It contains a transgene that includes a coding sequence and a promoter operable in the cells of a human patient. Lentiviral gene therapy is well known to those skilled in the art; recent scientific publications on the topic include Milone and O'Doherty, (2018) Leukemia 32, 1529-1541; Yaniez-Munioz et al. (2006) Nature Medicine 12, 348-353; Aiuti et al. (2013), Science 341(6148), DOI: 10.1126 / science.1233151).

[0011] The term "functional variant" as used in the context of this specification refers to a variant of a gene encoding a polypeptide, where a dysfunctional or non-functional variant of this gene is present in the patient, but the dysfunctional or non-functional variant does not serve a specific biological function in the patient. In stimulated phagocytes of healthy individuals, gp91phox protein (encoded by CYBB gene), p22phox protein (encoded by CYBA gene), p47phox protein (encoded by NCF1 gene), p40phox protein (encoded by NCF4 gene), p67phox protein (encoded by NCF2 gene) are combined to form an enzyme complex called NADPH oxidase. This NADPH oxidase has catalytic activity and is essential for the production of reactive oxygen species (ROS) by phagocytes. Rac2 protein (encoded by RAC2 gene) is required to induce the formation of NADPH oxidase enzyme complex upon cell stimulation. Mutations in any of these genes can result in the synthesis of misfolded proteins or the absence of one gene product, which ultimately results in the patient cells being unable to form an active NADPH oxidase complex and therefore unable to generate ROS, causing the CGD phenotype. The functional variants encoded by the gene therapy vectors can complement or replace the dysfunctional or non-functional variants, restoring NADPH oxidase function. [Prior art documents] [Non-patent literature]

[0012] [Non-Patent Document 1] Suliaman et al. (2009) Pediatric Asthma, Allergy & Immunology 22, 21-26 [Non-Patent Document 2] Ahlin et al. (1995) Acta Paediatr 84, 1386-1394 [Non-Patent Document 3] Kuhns et al. (2010) New Engl J Med 363 (27) 2600-10 Summary of the Invention [Means for solving the problem]

[0013] Summary of the Invention Based on this background, it is an object of the present invention to provide efficient means for the treatment of genetic disorders in chronic granulomatous diseases.

[0014] This object is achieved by the subject matter of the independent claims together with further advantageous features as presented in the dependent claims.

[0015] A first aspect of the present invention relates to isolated human hematopoietic stem cells (HSCs) or progenitor cells, in particular CD-34 positive hematopoietic stem cells, which can be transduced with a lentiviral vector to differentiate into myeloid lineage cells. - a nucleic acid sequence encoding a functional variant of a dysfunctional polypeptide selected from the group comprising gp91phox, p22phox, p40phox, p47phox, p67phox and Rac2; of, - a promoter sequence operable in a human cell, wherein said promoter comprises or essentially consists of the miR223 promoter sequence (SEQ ID NO: 01); under the transcriptional control of

[0016] miR223 promoter sequence (SEQ ID NO:01) [ka]

[0017] In certain embodiments, the cells are provided for the treatment of chronic granulomatous disease and the vector comprises a nucleic acid sequence encoding a functional variant or multiple functional variants of gp91phox (UniProt No. P04839), p22phox (UniProt No. P13498), p40phox (UniProt No. Q15080), p47phox (UniProt No. P14598), p67phox (UniProt No. P19878) and / or Rac2 (UniProt No. P15153).

[0018] In certain embodiments, the vector does not comprise a lentiviral promoter / enhancer element.

[0019] The term "enhancer element" in the context of the present specification refers to a short nucleic acid sequence that can be bound by an activator protein so as to increase the likelihood that transcription of a particular sequence, in particular a promoter sequence, will occur.

[0020] The vector may be based on or derived from an alpharetroviral vector, a gammaretroviral vector, a lentiviral vector, or an adeno-associated virus-based vector. In certain embodiments of the gene therapy vectors of the present invention, the vector is based on or derived from a lentiviral vector.

[0021] In one embodiment of the gene therapy vector of the present invention, said vector comprises or consists essentially of a nucleic acid characterized by SEQ ID NO:02.

[0022] SEQ ID NO:02: Lenti_mir223_p47phox_PRE4_KAN(UZH1p47CGD) 8688bp (Sequence elements shown in font in the 5' to 3' direction:) Lowercase font: CMV promoter; Lowercase underlined: Lentiviral LTR: 5'U5; Lowercase italics: Lentiviral leader sequence; Uppercase font: miR223 promoter; Uppercase underlined: Kozak sequence; Uppercase italics: p47phox open reading frame; Lowercase italics underlined: Restriction site; Lowercase: WPRE element; Lowercase italics underlined: Restriction site; Lowercase underlined: Lentiviral LTR: 3'U3; Lowercase italics: Lentiviral LTR: 3'R; Lowercase italics bold: Lentiviral LTR: 3'U5; Lowercase: [ka] [ka] [ka] [ka]

[0023] The stem or progenitor cells are obtained from a patient suffering from CGD and transduced with a gene therapy vector of the invention.

[0024] In certain embodiments, the isolated human myeloid stem or progenitor cells according to the invention are human CD-34 positive cells. Long-term repopulating hematopoietic stem cells are enriched in human CD34+ bone marrow cell populations, while cells with long-term engraftment potential in normal adult mice are Lin-, c-kit+, Sca-1+ and CD34- (Sato T., Laver JH & Ogawa M. (1999) Blood 94: 2548-2554). Human and mouse stem cells differ not only in surface marker expression, but also in growth conditions (culture medium, cytokines...) for cell expansion and viral transduction.

[0025] A further aspect of the present invention relates to a method for producing human progenitor cells capable of differentiating into monocyte or macrophage cells, the method comprising the steps of: - providing ex vivo CD34+ HSCs obtained from a patient suffering from CGD; and - said CD34+ HSCs, a coding nucleic acid sequence encoding a functional variant of a polypeptide selected from gp91phox, p22phox, p40phox, p47phox, p67phox and Rac2; said coding sequence comprising: a promoter sequence operable in a human cell, in particular a myeloid cell, wherein said promoter sequence comprises or essentially consists of the miR223 promoter sequence (SEQ ID NO: 01); A coding sequence under the transcriptional control of A lentiviral vector comprising The method includes the step of transducing with

[0026] The present invention also relates to a method of treating a patient diagnosed with chronic granulomatous disease, the method comprising: - providing CD34+ HSCs isolated from said patient; - These CD34+ HSCs, a coding nucleic acid sequence encoding a functional variant of a polypeptide selected from gp91phox, p22phox, p40phox, p47phox, p67phox and Rac2; said coding sequence comprising: a promoter sequence operable in a human cell, in particular a myeloid cell, wherein said promoter sequence comprises or essentially consists of the miR223 promoter sequence (SEQ ID NO: 01); the coding sequence being under the transcriptional control of transducing with a lentiviral vector comprising - administering said CD34+ HSCs to said patient; Includes:

[0027] The patient's native nucleic acid sequence encoding a dysfunctional polypeptide (which causes CGD) is complemented by a "healthy" nucleic acid sequence encoding a functional polypeptide by transducing CD34+ cells with the vector of the invention. The so-transduced (and complemented) HSC or progenitor cells are then returned to the patient.

[0028] The vectors of the invention can be used to transduce autologous CD34+ HSCs or hematopoietic progenitor cells that can differentiate into myeloid cells (such as monocytes, macrophages, or neutrophils). The CD34+ cells are obtained from a patient suffering from the genetic disease. The transduced HSCs are returned to the patient to undergo division and differentiation into myeloid cells.

[0029] The genetic disease treated by the present invention is chronic granulomatous disease, and the vector or HSC or hematopoietic progenitor cells capable of differentiating into myeloid cells, particularly monocytes / macrophages or neutrophils, contain a nucleic acid sequence encoding a functional variant or functional variants of a gene selected from the group including gp91phox, p22phox, p40phox, p47phox, p67phox and Rac2. The HSC or hematopoietic progenitor cells contain or are transduced by the vector.

[0030] According to a further aspect of the invention, there is provided a method for correcting a CGD phenotype in myeloid cells, comprising providing an HCS or hematopoietic progenitor cells of the invention, and administering the HCS or hematopoietic progenitor cells of the invention to a patient suffering from the disease.

[0031] In certain embodiments, the HCS or hematopoietic progenitor cells of the invention are provided by obtaining HCS or hematopoietic progenitor cells from a patient suffering from CGD and transducing said HCS or hematopoietic progenitor cells with a vector identified herein.

[0032] The genetic disease in myeloid cells is CGD, and the HCS or hematopoietic progenitor cells obtained from the patient contain or are transduced with a vector comprising a nucleic acid sequence encoding a functional variant or multiple functional variants of gp91phox, p22phox, p40phox, p47phox, p67phox and / or Rac2.

[0033] The transduced HCS or hematopoietic progenitor cells are then returned to the patient.

[0034] item 1. Isolated human hematopoietic stem or myeloid progenitor cells transduced with a lentiviral vector, said lentiviral vector comprising: - a coding nucleic acid sequence encoding a functional variant of a polypeptide selected from gp91phox, p22phox, p40phox, p47phox, p67phox and Rac2; - a promoter sequence operable in a human cell, in particular a myeloid cell, said promoter sequence comprising or consisting essentially of the miR223 promoter sequence (SEQ ID NO: 01); 1. An isolated human hematopoietic stem or myeloid progenitor cell comprising under the transcriptional control of

[0035] 2. The isolated human hematopoietic stem or myeloid progenitor cell according to item 1, wherein the lentiviral vector comprises or essentially consists of a nucleic acid sequence characterized by SEQ ID NO: 02.

[0036] 3. The human hematopoietic stem cell or myeloid progenitor cell of any one of paragraphs 1 or 2, wherein the cell is a CD34 positive hematopoietic stem cell.

[0037] 4. A method for preparing a therapeutic cell preparation, the method comprising: a. providing a preparation of cells, including hematopoietic stem cells, isolated from a patient suffering from chronic granulomatous disease associated with a genetic defect associated with a defective gene encoding a polypeptide selected from gp91phox, p22phox, p40phox, p47phox, p67phox and Rac2; b. The preparation of cells is i. a coding nucleic acid sequence encoding a functional variant of a polypeptide selected from gp91phox, p22phox, p40phox, p47phox, p67phox and Rac2; ii. A promoter sequence operable in a human cell, particularly a myeloid cell, wherein the promoter sequence comprises or essentially consists of the miR223 promoter sequence (SEQ ID NO: 01); transducing with a lentiviral vector comprising under the transcriptional control of The method includes:

[0038] 5. An isolated human hematopoietic stem cell or myeloid progenitor cell according to any one of items 1 to 3, or a cell preparation obtained by the method according to item 4, for use in the treatment or prevention of chronic granulomatous disease.

[0039] 6. The isolated human hematopoietic stem or myeloid progenitor cells for use in the treatment or prevention of chronic granulomatous disease according to item 5, wherein the cells are autologous cells.

[0040] The present invention is further illustrated by the following examples and figures from which further embodiments and advantages may be derived. These examples are meant to illustrate the invention but not to limit its scope. [Brief description of the drawings]

[0041] [Figure 1] 1 and 2 show certain embodiments of vectors for use in the present invention. [Diagram 2] Same as above.

[0042] [Diagram 3] FIG. 3 shows that miR223-driven p47phox expression during gammaretroviral gene therapy restores ROS generation and E. coli killing in human granulocytes.

[0043] [Figure 4] FIG. 4 shows restoration of ROS generation in human macrophages from p47phox-deficient CGD patients following transduction of patient-derived monocytes upon lentiviral transduction of monocytes.

[0044] [Diagram 5] Figure 5. DNA methylation of the silencing-sensitive SFFV enhancer / promoter (CpG island) and part of the p47phox transgene in human CD34+ cells after 4 weeks in cell culture. CD34+ cells were transduced with a gammaretrovirus and cultured for 4 weeks. DNA was isolated, treated with sodium bisulfite and amplified in a PCR reaction. It was then sequenced. All horizontal lines represent sequencing results with the information content reduced to CpG dinucleotides: open circles = unmethylated CpG; closed circles = methylated CpG.

[0045] [Figure 6] Figure 6 Transduction of human HSCs from healthy donors with lentiviral vectors encoding fluorescent green protein (GFP) under the control of the miR223 promoter or the SFFV promoter, followed by miR223-driven GFP expression in CD11b+ cells during myeloid differentiation into CD11b+ cells in liquid cell culture. EXAMPLES

[0046] Working Example

[0047] The present invention is based in particular on the surprising finding that the use of miR223 promoter in gene therapy vectors advantageously overcomes the known problems of transactivation and / or epigenetic inactivation.This is particularly shown by the LV-SIN gene therapy vector for autosomal recessive p47phox-deficient CGD.It should be noted that lentiviral transduction of human HSCs with lentiviral vectors encoding p47phox under the control of miR223 promoter for p47phox CGD treatment has never been shown before.

[0048] Vectors for preclinical use to characterize transgene expression Data confirming highly myeloid-specific transgene expression was generated with gammaretroviral and lentiviral vectors. An example of the gammaretroviral vector used is shown in Figure 1. The ΔLNGFR-2A-p47phox fusion construct produces two distinct proteins (cytoplasmic p47phox, and ΔLNGFR on the cell surface), both derived from a single mRNA(v). An example of the lentiviral vector used is shown in Figure 2.

[0049] Preventing transactivation in HSCs by restricting expression to myeloid cells Myeloid lineage specificity of miR223 promoter activity demonstrated in animal studies Lineage-negative bone marrow cells were isolated from p47phox − / − mice and transduced with gammaretroviral vectors encoding p47phox or ΔLNGFR-2A-p47 fusion constructs under the control of the miR223 promoter (Figure 1). Recipient p47 − / − mice were lethally irradiated and reinjected intravenously with the transduced bone marrow cells. Six weeks after reinfusion, p47phox expression and ROS generation were restored in granulocytes, indicating successful engraftment of the transduced bone marrow cells (Brendel et al. (2013) Hum Gene Ther Methods. 24: 151-159).

[0050] In parallel, lineage-negative bone marrow cells were isolated from gp91phox- / - mice and transduced with the LV-SIN vector encoding gp91phox under the control of the miR223 promoter. Recipient gp91phox- / - mice were lethally irradiated and reinjected intravenously with the transduced bone marrow cells. The transduced cells engrafted and led to restoration of transgene expression and ROS production in peripheral granulocytes of these mice (Brendel et al. (2013) ibid.).

[0051] Analysis of transgene expression revealed a striking lineage specificity conferred by the miR223 promoter in both animal studies, restricting transgene expression almost exclusively to myeloid cells (Brendel et al. (2013) ibid.).

[0052] Restoration of phagocyte function by miR223-driven transgene expression in primary patient-derived material In the animal experiments mentioned above, both miR223-driven gp91phox expression (lentiviral vector) and miR223-driven p47phox expression (gammaretroviral vector) restored ROS generation in phagocytes upon gene therapy treatment in the corresponding animal models.

[0053] Reconstitution of ROS generation and E. coli killing was tested in human granulocytes after treatment of HSCs with gammaretroviral vectors and differentiation of the cells in cell culture. To detect cytoplasmic p47phox transgene expression in living granulocytes, we generated gammaretroviral vectors encoding a fusion construct consisting of a ΔLNGFR surface marker linked to p47phox via the 2A sequence derived from foot-and-mouth disease virus. This fusion construct leads to the synthesis of two proteins from one mRNA transcript in one translation process: the cytoplasmic p47phox protein and the ΔLNGFR surface marker. This co-expression allows the indirect detection of p47phox by ΔLNGFR surface staining (Wohlgensinger et al. (2010) Gene Ther. 17: 1193-1199). In the gammaretroviral vectors utilized, we expressed this fusion construct under the control of either the constitutively active SFFV promoter or the miR223 promoter.

[0054] We transduced human HSCs from p47phox-deficient CGD patients with these gammaretroviral vectors and subsequently differentiated the cells into granulocytes in cell culture. Differentiation was confirmed by FACS measurement of granulocyte CD11b surface marker expression. Detection of the ΔLNGFR surface marker indirectly indicated p47phox expression.

[0055] ROS generation was detected by dihydrorhodamine 123 oxidation (DHR) assay upon stimulation of cells with PMA or with E. coli. ROS generation in ex vivo differentiated granulocytes was observed only in ΔLNGFR-positive cells (FIG. 3).

[0056] Differentiated (CD11b+) and ΔLNGFR positive granulocytes, as well as differentiated and ΔLNGFR negative (non-transduced) cells, were isolated by FACS sorting and applied to an E. coli killing assay as described (Ott et al. (2006) Nat Med 12: 401-409). In this assay, successful E. coli killing results in an increase in OD420nm. Importantly, using the gammaretroviral SIN p47phox miR223 vector, p47phox transgene expression, ROS production and E. coli killing were restored to similar amounts as the gammaretroviral SIN p47phox vector, in which transgene expression is driven by the strong constitutively active SFFV promoter (Figure 3).

[0057] Figure 3 shows that miR223-driven p47phox expression restores ROS generation and E. coli killing in human granulocytes. Lineage-negative HSCs from p47phox CGD patients were gammaretrovirally transduced with ΔLNGFR / p47phox co-expression constructs under SFFV or miR223 promoter control and differentiated into CD11b+ granulocytes. ΔLNGFR / p47phox-expressing granulocytes were FACS-sorted and applied to E. coli killing assay. An increase in OD420nm indicates restoration of E. coli killing.

[0058] Restoration of phagocyte function is also shown in primary derived p47phox CGD patient material. The lenti_miR223_p47_WPREmut6 vector (Figures 2 and 4) was used to transduce monocytes derived from p47phox-deficient CGD patients. Transduced monocytes were differentiated into macrophages for 7 days, giving rise to CD14+ / CD206+ macrophages. p47phox transgene expression was confirmed by intracellular FACS staining and ROS generation upon PMA stimulation was confirmed in a nitroblue teterazolium (NBT) reduction assay (Figure 4).

[0059] Figure 4 illustrates the restoration of ROS generation in human macrophages from p47phox-deficient CGD patients. Monocytes from p47phox CGD patients were isolated from blood, transduced with the above LV-SIN lenti_miR223_p47_WPREmut6 vector and differentiated into macrophages. Differentiation into CD14+ / CD206+ macrophages and restoration of p47phox expression was confirmed by FACS (left). Restoration of ROS generation upon PMA stimulation was confirmed by NBT assay. Yellow arrow: NBT-positive, i.e. ROS-generating macrophages, white arrow: NBT-negative macrophages.

[0060] Preventing epigenetic inactivation of transgene expression Kinetics of epigenetic inactivation in vivo and in cell culture In the first transiently successful clinical X-CGD gene therapy trial, transgene expression was driven by a gammaretroviral promoter / enhancer within the viral LTR. Epigenetic inactivation of transgene expression began approximately 1 year after gene therapy and revealed a growing discrepancy between gene marking and gene function within the next 1.5 years (Siler et al. (2015) Current Gene Therapy 15: 416-427). The promoter / enhancer sequence within the LTR of the utilized gammaretroviral vector corresponds to the SFFV promoter / enhancer utilized in various vectors as a ubiquitously active promoter. This SFFV promoter was tested for its sensitivity to epigenetic modifications in CGD animals 3 and 6 months after gene therapy treatment. Epigenetic SFFV promoter inactivation by DNA methylation in mice was already detectable after 3 months and increased over time thereafter (Zhang et al. (2010) Mol Ther 18: 1640-49).

[0061] Cells in a very primitive differentiation state, such as embryonic carcinoma cell lines (He et al. (2005) J Virol 79: 13497-508), embryonic stem cells (Liew et al. (2007) Stem Cells 25: 1521-28) and induced pluripotent stem cells (iPSCs) (Hotta & Ellis (2008) J Cell Biochem 105: 940-8), are known for their high DNA methylation activity. Epigenetic inactivation of the SFFV promoter in lentiviral vectors by P19 embryonic carcinoma cells is already detectable 6-12 days after transduction of the cells (Zhang et al. (2010) ibid.).

[0062] Novel anti-silencing activity of the miR223 promoter We tested the sensitivity of the miR223 promoter to DNA methylation in P19 cells and p47phox iPSC cell lines.

[0063] In lentiviral vectors (Figure 2), an average of 57.1% of CpGs in the miR223 promoter and more than 70% of CpGs in the SFFV promoter were methylated in P19 cells after 20 days (unpublished data). Since P19 cells cannot differentiate into myeloid lineages (to phagocytes) and the miR223 promoter is a myeloid-specific promoter, we tested these lentiviral vectors encoding p47phox under the control of the miR223 promoter in p47phox CGD patient-derived iPSCs (iPSC CGD1.1; Jiang et al. (2012) Stem Cells 30: 599-611), because these cells have high DNA methylation activity and can be expanded into phagocytes.

[0064] iPSC CGD1.1 cells were transduced with a lentiviral vector encoding p47phox under the control of the miR223 promoter (see Table 1 below) at a multiplicity of infection of 2 (MOI 2, i.e., twice as many viral particles as cells).

[0065] Starting on day +13 post-transduction, iPSCs were first expanded into "embryoid bodies" and then further expanded into "monocyte factories" that released monocytes. The first monocytes could then be harvested starting on day +43 post-transduction. The harvested monocytes were further differentiated into macrophages by incubation in medium supplemented with M-CSF for 7 days.

[0066] The average gene therapy vector copy number (VCN) per genome was determined by qPCR at day +16 in iPSCs and at day +85 in harvested monocytes. p47phox expression was quantified by flow cytometry (FACS) analysis at days +6, +10, +16, and +20 in iPSCs, at day +23 in CD133+ stem cells in embryoid bodies, at day +104 in CD38dim / CD34+ cells in embryoid bodies, at day +52 in CD14+ cells, at day +48 in CD15+ cells, and at day +68 in CD206+ cells. The percentage of p47phox-positive cells per vector copy number and the FACS-derived mean fluorescence intensity (MFI) of p47phox-positive cells were determined to compare miR223 promoter activity in individual cell populations.

[0067] Analysis of p47phox expression at different differentiation stages revealed that miR223-driven p47phox expression was barely detectable with a percentage of p47 positive cells per vector copy number of 0.67±0.33 (standard deviation) on average for stem cell level (iPSC, CD133+ cells, CD34+ cells) (n=6). During myeloid differentiation, p47phox expression was strongly increased with a percentage of p47 positive cells per vector copy number of 5.26±0.66. This increase in the percentage of p47phox expressing cells was paralleled by a strong increase in FACS signal intensity (MFI). This strongly indicates activation of the miR223 promoter from the stem cell level during differentiation into myeloid cells.

[0068] Gene therapy-mediated restoration of p47phox production in granulocytes, monocytes, and macrophages generated from transduced p47phox CGD iPSCs resulted in restoration of ROS production, as revealed in dihydrorhodamine 123 oxidation (DHR) assays and in nitroblue tetrazolium reduction (NBT) assays.

[0069] In parallel with the analysis of miR223 promoter activity on different levels of differentiation between iPSCs and myeloid cells (granulocytes, monocytes, macrophages), DNA methylation analysis of the miR223 promoter in the gene therapy vectors and of the endogenous miR223 promoter gene in the genome of the transduced cells was performed in iPSCs at day +20 post-transduction and in monocytes derived from transduced iPSCs at differentiation day +85 post-iPSC transduction. Analysis of iPSCs and iPSC-derived monocytes upon transduction with a vector containing p47phox under the control of a silencing-sensitive SFFV promoter served as controls.

[0070] This analysis (Table 1) revealed that at the stem cell level, in parallel with P19 cells, the majority (>80%) of the CpG dinucleotides in the miR223 promoter were methylated within the gene therapy vector encoding the miR223 promoter and within the native endogenous miR223 gene promoter in the genome of the transduced cells. On the functional level, the methylated miR223 promoter was inactive, as shown by p47phox expression analysis. [Table 1] Table 1: DNA methylation analysis of gene therapy vector-encoded miR223 promoter and native miR223 gene promoter in iPSC (induced progenitor stem cell) level (day +20) and iPSC-derived monocytes at day +85 after iPSC transduction. A vector encoding a silencing-sensitive SFFV promoter served as a control. The changes in miR223 promoter DNA demethylation were statistically significant.

[0071] Surprisingly, we found that both the miR223 promoter, which was initially methylated within the gene therapy vectors analyzed, and the native genomic miR223 gene promoter, were demethylated upon myeloid differentiation (Table 1).

[0072] In parallel with the increase in promoter activity, the percentage of CpG dinucleotide methylation within the miR223 promoter decreased from 87% to 31%.

[0073] In our previous gammaretrovirus X-CGD (a gp91phox-deficient form of CGD) clinical gene therapy trial, transgene expression was driven by a constitutively active (SFFV) promoter. A graded increase in promoter methylation encoded by the gene therapy vector caused a clinically graded decrease in therapeutic efficacy over time (Ott et al. (2006) Nat Med 12: 401-409; Siler et al. (2015) Curr Gene Ther 15: 416-427). In this trial, the constitutively active promoter was methylated in HSCs, resulting in the release of HSCs from bone marrow with promoter methylation in the gene therapy vector and therefore reduced therapeutic transgene expression.

[0074] When myeloid-specific miR223 promoter is used as an internal promoter in gene therapy vector, the methylation pattern surprisingly observed shows that the promoter is inactive and methylated at stem cell level.Only during differentiation, the miR223 promoter is activated and demethylated.This strongly indicates that this promoter can provide long-term efficacy.Since there is a continuous flux of myeloid cells derived from HSC released from bone marrow, in these newly generated cells, the miR223 promoter is actively demethylated before being released from bone marrow.

[0075] Dynamics of promoter DNA methylation In cell culture experiments, we introduced the SFFV promoter in human CD34+ bone marrow cells by gammaretroviral transduction, cultured the cells for 4 weeks, and then quantified DNA methylation. We could not detect significant amounts of DNA methylation in human CD34+ cells after 4 weeks in cell culture (Figure 5).

[0076] It was reported that in vivo silencing of the SFFV promoter in mouse bone marrow was detectable 3 months after gene therapy and further progressed over the following 3 months (Zhang et al. (2010) ibid.).

[0077] Retroviral vectors are reported to be quickly silenced in pluripotent stem cells, including early preimplantation embryos, embryonic stem (ES) cells and embryonic carcinoma (EC) cells (Pannell D, Ellis J. (2001) Rev Med Virol 11: 205-217). The embryonic carcinoma cell line P19 has been intensively used to test the sensitivity of promoters in gene therapy vectors to silencing (Knight et al. (2012) J Virol 86: 9088-95; Brendel et al. (2012) Gene Therapy 19: 1018-29; Zhang, Santilli & Thrasher (2017) Sci Rep. 7: 10213; Zhang et al. (2010) ibid.). Silencing of the SFFV promoter has been consistently reported to be complete already after 12-17 days in this model.

[0078] Since P19 cells cannot be differentiated, this model is not suitable for testing tissue-specific promoters. On the other hand, it is known that retroviral expression is silenced in induced pluripotent stem cells (iPSCs), which have the ability to be differentiated into any cell type in cell culture (Maherali et al. (2007) Cell Stem Cell 1: 55-70; Okita, Ichisaka & Yamanaka (2007) Nature 448: 313-317; Wernig et al. (2007) Nature 448: 318-324). iPSCs were generated from CGD patient material. These iPSCs were shown to have the same genetic defects as those found in the patient material. The cells can be differentiated into mature monocytes and macrophages, and in contrast to monocytes and macrophages derived from non-CGD iPSCs, monocytes and macrophages derived from the CGD iPSCs do not exhibit reactive oxygen species (ROS) production, as is true for monocytes and macrophages derived from CGD patients (Jiang et al. (2012) Stem Cells 30:599-611).

[0079] Upon retroviral introduction of the SFFV promoter into CGD iPSCs, the SFFV promoter was silenced in vivo in human bone marrow starting after 10 months in the X-CGD clinical trial, after 3-6 months in mouse bone marrow, after 12-17 days in P19 cells, and within 20 days in CGD iPSCs (Haenseler et al. (2018) Matters; doi.: 10.19185 / matters.201805000005). Upon differentiation of CGD iPSCs bearing the SFFV promoter, SFFV promoter-driven transgene expression was strongly reduced in terminally differentiated monocytes and macrophages. This indicates that 1) iPSCs have strong promoter silencing activity, and 2) the SFFV promoter, once silenced, remains silenced upon cell differentiation from iPSCs to monocytes (Haenseler et al. (2018) Matters; doi.: 10.19185 / matters.201805000005). iPSCs have been used to develop a system that prevents silencing of ubiquitously active promoters such as the SFFV promoter. These anti-silencing systems were mainly based on the use of insulators (Sanchez-Hernandez et al. (2018) Mol Ther Nucleic Acids 13: 16-28) or ubiquitous chromatin opening elements (UCOEs) (Pfaff et al. (2013) Stem Cells 31: 488-99; Ackermann et al. (2014) Biomaterials 35: 1531-42; Hoffmann et al. (2017) Gene Ther. 24: 298-307).

[0080] Taken together, iPSCs are a relevant model for the analysis of gene therapy vector methylation, but this model has never been applied to analyze the susceptibility of tissue-specific promoters to silencing.

[0081] Analysis of tissue-specific miR223 promoters for their susceptibility to silencing To analyze the sensitivity to silencing of the miR223 promoter, we utilized iPSCs generated from patients suffering from p47phox-deficient CGD and capable of differentiating into monocytes and macrophages that exhibit the CGD phenotype (p47phox CGD iPSCs) (Jiang et al. (2012) Stem Cells 30:599-611).

[0082] p47phox CGD iPSCs were lentivirally transduced (day +1) with our gene therapy vector (UZH1p47CGD) or with a lentiviral vector encoding p47phox under the control of a constitutively active and silencing-resistant version of the SFFV promoter (Lenti UCOE 1662fwd SFFV p47). Transduced iPSCs were first differentiated into embryoid bodies (EBs) and then further differentiated into monocytes and macrophages. The average vector copy number (VCN) per cell was determined by qPCR in iPSCs at day +16 and in monocytes at day +85 after transduction. Transgene expression was monitored in CD133 positive stem cells in embryoid bodies on day +23, in CD38dim / CD34+ cells in embryoid bodies (which are comparable to HSCs) on day +104, in monocytes on day +52, and in macrophages on day +68 after transduction. p47phox expression was detected by FACS analysis upon intracellular staining of p47phox protein in combination with CD34, CD38, CD14 and CD206 surface staining. To correct for differences in transduction efficiency, the percentage of p47phox positive cells was divided by VCN.

[0083] p47phox transgene expression In iPSCs and the homolog of HSCs derived from iPSCs (i.e., CD38 in embryoid bodies) dim / CD34 highIn cells (hereafter referred to as "HSCs" in this context), the miR223 promoter in our gene therapy vector UZH1p47CGD resulted in significantly weaker p47phox transgene expression as measured by signal intensity, and a lower percentage of p47phox-positive cells per vector copy number. In contrast, in differentiated monocytes and macrophages, the signal intensity and the percentage of p47phox-positive cells per vector copy number were higher in transduced cells (see Table 2 below). [Table 2] Table 2: p47phox transgene expression in iPSC and iPSC-derived cell populations characterized by percentage of p47phox positive cells per vector copy number (CVN) and flow cytometry derived mean fluorescent signal intensity (MFI). Human p47phox negative iPSCs were transduced with lentivirus and expanded through embryoid bodies to monocytes and macrophages. Mean vector copy number (VCN) was determined in iPSCs and in iPSC-derived monocytes. Transgene expression was monitored in CD133+ stem cells, in HSC-like CD34+ cells in embryoid bodies, in monocytes, and in macrophages. p47phox expression was detected by FACS analysis upon intracellular staining. The percentage of p47phox positive cells was normalized for transduction efficiency by calculation of the percentage of p47 positive cells per VCN. miR223-driven p47phox expression showed faint expression in CD133+ and CD34+ cells, as well as an increase in expression upon differentiation as revealed by the percentage of p47phox positive cells, and in MFI as well.

[0084] Importantly, miR223 promoter-driven p47phox expression resulted in low background signals (percent positive cells / VCN) as well as expression intensity (MFI) in stem cells. The low background signals in stem cells indicate the excellent safety profile of UZH1p47CGD gene therapy vector.

[0085] Human HSCs from healthy donors were transduced with lentiviral vectors encoding GFP under the control of SFFV or miR223 promoters and subsequently differentiated into CD11b positive myeloid cells in liquid cell culture. GFP expression was analyzed in human HSC-derived CD11b positive cells by FACS analysis. Detection of GFP positive human HSC-derived myeloid cells (Figure 6, unpublished data) was consistent with a vector copy number (CVN) of 0.05, indicating transgene expression activity of the miR223 promoter in human HSC-derived myeloid cells as required for CGD gene therapy treatment.

[0086] Reconfiguring ROS production: ROS generation was monitored in monocytes and macrophages upon stimulation with PMA (monocytes) or PMA+fMLP (macrophages) by DHR oxidation and by NBT reduction assay. In the DHR assay, non-fluorescent dihydrorhodamine turns fluorescent upon oxidation by ROS. Fluorescent signal intensity was detected by FACS analysis. Correspondingly, in the FACS analysis, a shift to the right indicates restoration of ROS generation. In the NBT assay, the formation of a deep blue formazan precipitate indicates ROS generation. Monocytes / macrophages derived from non-transduced CGD iPSCs served as a negative control. Monocytes / macrophages obtained from CGD iPSCs served as a positive control. They were transduced with a vector (Lenti UCOE1662fwd SFFV p47) encoding p47phox under the control of a ubiquitously active and silencing-resistant version of the SFFV promoter.

[0087] miR223-driven p47phox expression by our gene therapy vector UZH1p47CGD resulted in the reconstitution of ROS generation and thus the correction of the CGD phenotype, as visualized both in the DHR assay and in the NBT assay.

[0088] Silencing (DNA methylation) analysis in iPSC models: We utilized p47- / - iPSCs to test for methylation of their gene therapy vector (UZH1p47CGD) and for transgene expression activity during iPSC differentiation into phagocytes. p47phox-negative iPSCs were transduced with lentivirus and expanded into monocytes. DNA was isolated from transduced iPSCs (day +20) and from iPSC-derived monocytes (day +97). For DNA methylation analysis, isolated DNA was exposed to sodium bisulfite, which converts only unmethylated cytosines to uracil. Subsequent PCR amplification converts uracil to thymidine. Comparison of the original sequence with the sequence after bisulfite conversion reveals DNA methylation. That is, in all methylated sequences, cytosines are detected by sequencing, whereas in unmethylated sequences, thymidines are detected.

[0089] DNA methylation analysis was performed in iPSCs and iPSC-derived monocytes upon transduction with a gene therapy vector (UZH1p47CGD) encoding p47phox under miR223 control. Methylation analysis covered the entire miR223 promoter sequence and a portion of the p47phox transgene. Furthermore, we analyzed the DNA methylation of the native miR223 gene promoter sequence in the iPSC genome.

[0090] Importantly, in iPSCs, both the virally encoded and native miR223 promoters were nearly completely methylated within 20 days. Thus, p47phox transgene expression was extremely low in CD133+ iPSCs and in iPSC-derived CD34+CD38- stem cells (see Table 1 above).

[0091] There was no significant difference in the degree of methylation between the gene therapy vector-encoded miR223 promoter sequence and the native miR223 promoter, either on the iPSC level or in monocytes. Surprisingly, and in contrast to the results obtained with the SFFV promoter (Haenseler et al. (2018) Matters; doi.: 10.19185 / matters.201805000005), we found that upon differentiation of iPSCs into terminally differentiated cells, the methylation of both the viral and the native miR223 promoters was significantly reduced. This indicates active demethylation upon differentiation (Table 1) and thus upon activation (Table 2). Extrapolated to the long-term in vivo situation, this finding indicates long-term activity of the miR223 promoter, as it is silenced in quiescent HSCs, and the miR223 promoter is predicted to become active upon HSC activation and differentiation. As mentioned earlier, a UCOE-based system was developed that could prevent silencing of the SFFV or Chim promoter (Zhang, Santilli & Thrasher (2017) Sci Rep 7: 10213). However, the UCOE system is embedded in a retroviral gene therapy vector and has the risk of altering DNA methylation of DNA near the retroviral integration site in HSCs as well. This activity could activate oncogenes near the integration site of the gene therapy vector in HSCs in all outcomes. In contrast to the UCOE system, the miR223 promoter in the vector UZH1p47CGD, which was adapted to the surrounding methylation pattern only in stem cells and upon differentiation, was demethylated. This is a remarkable safety feature.

Claims

1. 1. An isolated human hematopoietic stem or myeloid progenitor cell transduced with a lentiviral vector, the lentiviral vector comprising: - a coding nucleic acid sequence encoding a polypeptide selected from gp91phox and p47phox; of, - the miR223 promoter sequence according to SEQ ID NO: 01 1. An isolated human hematopoietic stem or myeloid progenitor cell comprising under the transcriptional control of

2. The isolated human hematopoietic stem or myeloid progenitor cell of claim 1 , wherein the lentiviral vector comprises the nucleic acid sequence set forth in SEQ ID NO:

02.

3. The human hematopoietic stem cell or myeloid progenitor cell of claim 1 or 2, wherein the cell is a CD34 positive hematopoietic stem cell.

4. 1. A method for preparing a therapeutic cell preparation, the method comprising: a. providing a preparation of cells, including hematopoietic stem cells, isolated from a patient suffering from chronic granulomatous disease associated with a genetic defect associated with a defective gene encoding a polypeptide selected from gp91 and p47; b. The preparation of cells is: i. a coding nucleic acid sequence encoding a polypeptide selected from gp91phox and p47phox; ii. miR223 promoter sequence as set forth in SEQ ID NO:01 transducing with a lentiviral vector comprising under the transcriptional control of The method includes:

5. The method of claim 4, wherein the preparation of cells containing hematopoietic stem cells is a preparation of CD34-positive hematopoietic stem cells.

6. 6. The isolated human hematopoietic stem or myeloid progenitor cells according to any one of claims 1 to 3, or a cell preparation obtained by the method according to claim 4 or 5, for use in the treatment or prevention of chronic granulomatous disease.

7. 7. The isolated human hematopoietic stem or myeloid progenitor cells for use in the treatment or prevention of chronic granulomatous disease according to claim 6, wherein the cells are autologous cells.